A comparison of p-tau assays for the specificity to detect tau changes in Alzheimer's disease.

ABSTRACT:

Introduction

We evaluated differences in p-tau levels between Alzheimer's disease (AD), a condition with brain-specific changes in p-tau, and amyotrophic lateral sclerosis (ALS), a condition associated with increases in peripheral p-tau levels.

Methods

Cerebrospinal fluid and plasma from 668 participants were analyzed using immunoassays specific for the low-molecular-weight (LMW) tau isoforms present in the brain (i.e., p-tau217_Lilly, p-tau181_Lilly) and those that detect both LMW- and high-molecular-weight (HMW) tau expressed in the peripheral nervous system (i.e., p-tau217_AlzPath, p-tau181_UGOT).

Results

Increases in plasma p-tau in ALS versus controls were significantly smaller for the LMW-specific p-tau assays (15.9%-20.5%

SUBMITTER: Janelidze S 

PROVIDER: S-EPMC12035549 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature